Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by whisky11on Apr 29, 2021 9:54am

207 Views

Post# 33090177

Phase 1 will get Claritas to phase 2 antiviral medication

and that includes coronavirus common cold and flu, this viruses will deal with humanity forever.
The reason is that they can jump to animals and back to people. As I understand it phase1 will we be used to develop medication for treatment of PAH and viruses.

Highlights

Claritas is developing R-107 for the treatment of viral infections, and will now also develop R-107 for the treatment of PAH.
PAH is a lethal condition, resulting from high blood pressure in the lungs.
The worldwide market for treatment of PAH exceeds $6 billion per year and is projected to grow to $9.8 billion by 2027.
R-107 is the first and only agent to demonstrate a durable reversal of established disease in a validated animal model of PAH.
Claritas’ development strategy for R-107 in PAH is designed to expedite the potential monetization of this asset.